 liver failure,  risk of nausea, hand and foot skin reactions (HFSR), rash, fatigue, diarrhea, adverse events, cancer free survival, lesion size, fatigue, EORTC, pain (QLQ-C30), insomnia, EQ-5D VAS, quality of life, jaundice, abdominal swelling, constipation, appetite loss, fever, complications, functional scale of sex life, hypertension, proteinuria, pruritus, increased aspartate aminotransferase,  increased alanine amintransferase (ALT),  increased serum bilirubin, abdominal pain,  cough, thromboplastinemia, weight loss, epilepsy, palmar rash and trombocytopenia, hypertension, thrombocytopenia,  proteinuria, gastrointestinal disorders (bleeding), infections, dysphonia, hepatic encephalopathy, hepatic failure, ascites,  haemorrhage, hypothyroidism, brain haemorrhage, sepsis, intestinal failure, respiratory failure, cerebrovascular accident, cardiovascular arrest, myocardial infarction, sudden death, discontinuation due to adverse events,  hepatic dysfunction, pharmacokinetic interactions, CYP3A4 induction, P-gp substrate interaction, CYP2B6 substrate interaction, CYP2C8 substrate interaction, CYP2C9 substrate interaction,  treatment suspension due to adverse events, dose reduction due to adverse events, secondary cancer,  rash, skin desquamation, hypocalcaemia, alopecia, lymphopenia, anorexia, hypophosphataemia, dry skin, arthralgia, increased amylase, increased lipase, folliculitis, leukopenia, hypokalaemia, hyponatraemia, hypoglycaemia,  dysgeusia, tinnitus, congestive heart failure, flushing, rhinorrhoea, dysphagia, gastro-oesophageal reflux disease, keratoacanthoma, squamous cell cancer of the skin, dermatitis exfoliative, acne, hyperkeratosis, myalgia, muscle spasms, renal failure,  erectile dysfunction, asthenia, influenza-like illness, mucosal inflammation, transient increase in transaminases, hypertensive crisis, drug-induced hepatitis, dermatological toxicity, QT interval prolongation, hepatic impairment, wound healing complications, hepatotoxicity, acute generalised exanthematous pustulosis, aneurysm, artery dissection,  pharmacokinetic parameters, grade 3â€“4 adverse reactions, drug withdrawal, fatal adverse events, tumour haemorrhage, ischaemic stroke, respiratory failure, sudden death,  renal function, pancreatic function, adverse event rate per patient-year, non-inferiority, superiority, no significant comparative safety concerns, overall survival, progress free survival, disease progression, Length of Stay, day of missed work, Disease recurrence, health-related quality of life, time to progression, mortality, serious adverse events, costs, ICER, QALY,  5-year survival rate, 1-year survival rate, time to progression, time to symptom progression, disease control, partial response, minor response, stable disease, ICUR, 